190 results about "Antithrombotic" patented technology

The invention provides an anticoagulant coating for medical instruments, which can be used in the field of regenerative medical instruments. The prepared anticoagulant coating has short-term and long-term anticoagulant performance, and in addition, the thrombin responsive nanoparticles wrapped in the hydrogel coating can selectively release a factor Xa (FXa) inhibitor apixaban according to needs, so that thrombosis is inhibited in the middle stage of implantation. In-vitro and in-vivo experimental evidences show that after the material is implanted for a long time, an organized endodermis can be seen on the surface of the material, and the material has a special antithrombotic characteristic. The dynamic adjusting system has a multi-layer protection mechanism, and a new thought can be provided for designing the surface of a contact blood material adapting to environmental conditions.

The invention relates to ultra-small prussian blue nano-particles (T-USPB-C) carrying tirofian, a preparation method of the nano-particles and application of the nano-particles in preparation of drugs for reducing MVO and MIRI. According to the preparation method, the T-USPB-C is prepared by three steps. The T-USPB-C provided by the invention can carry tirofiban, and has catalase and superoxide dismutase simulated nano-enzyme activity. Moreover, the size of the nano-scale drug is required to reach a nano-scale size, and the drug can be efficiently cleared through kidney excretion, so that the potential long-term toxicity problem is minimized. The ultra-small prussian blue nanoparticle carrying the tirofian has an excellent active oxygen scavenging capability. Microvascular perfusion can be rapidly improved through the antithrombotic effect, then the protection effect is continuously achieved through the anti-oxidation and anti-inflammatory mechanism, and microvascular injury and MIRI are effectively prevented.

The invention belongs to the technical field of food or medicine, and particularly relates to a preparation method of nattokinase sustained-release microspheres, which comprises the following steps: mixing an emulsifier span-80 with liquid paraffin to obtain an oil phase; adding chitosan into an acetic acid solution to prepare a chitosan water solution as a water phase; dropwise adding the water phase into the oil phase to prepare W / O type emulsion, dropwise adding a cross-linking agent A into the emulsion to obtain chitosan microspheres, and taking a chitosan microsphere nattokinase solution and a cross-linking agent B to obtain nattokinase-chitosan core microspheres; mixing the nattokinase-chitosan core microsphere with a cortisol aptamer solution, and incubating to enable the aptamer to be combined on the surface of the nattokinase-chitosan core microsphere; and adding a casein-PEG copolymer solution and a cross-linking agent C into the microspheres to obtain the cortisol response type intelligent switch microspheres. The nattokinase release amount can be dynamically adjusted day and night, the circadian thrombus risk rhythm is matched, the anti-thrombus effect is remarkably improved, side effects are reduced, and the nattokinase can be widely applied to the fields of functional food and drugs.

The invention belongs to the technical field of biomedical materials, and particularly relates to a poly-4-methyl-1-pentene (PMP) gas-blood exchange membrane for an extracorporeal membrane oxygenation (ECMO) system, which realizes a long-acting antithrombotic function through a bionic interface construction technology. The invention aims to provide a bionic antithrombotic PMP gas-blood exchange membrane based on zwitter-ion gradient grafting, and through material and process innovation, the following problems existing in a traditional ECMO gas-blood exchange membrane: an antithrombotic coating is easy to fall off, and the long-term effect is insufficient; the risk of blood injury caused by dependence on heparin or anticoagulants; and the surface modification process destroys the membrane pore structure and air permeability.

The invention relates to the technical field of traditional Chinese medicine health-care products, and particularly discloses an earthworm protein peptide composition for improving vascular embolism and a preparation method thereof.The earthworm protein peptide composition is prepared from, by weight, 28-34 parts of earthworm protein peptide, 20-26 parts of active pharmaceutical ingredients, 1-5 parts of ginkgo biloba extract, 12-15 parts of corn oligopeptide powder and 4-8 parts of auxiliary materials; lumbricus protein peptide, active pharmaceutical ingredients, ginkgo biloba extract and corn oligopeptide powder are used as raw materials, a solubilizing component is added in the preparation process, the solubilizing component is prepared by mixing functional extract, nattokinase and tween-80 according to a certain proportion, the functional extract is prepared by coating grape seed extract with hydroxypropyl-beta-cyclodextrin, and the solubilizing component is prepared by mixing the functional extract, the nattokinase and the tween-80 according to a certain proportion. Through the synergistic effect of the components, the antithrombotic effect of the earthworm protein peptide composition is synergistically enhanced.

The invention belongs to the technical field of microorganisms and biological medicines, and particularly relates to a postbiotic preparation for improving vascular elasticity and relieving hypertension and thrombus as well as a preparation method and application of the postbiotic preparation. Specifically, a strain of lactobacillus rhamnosus is obtained through screening, a postbiotic preparation is successfully developed based on the strain, and tests prove that the lactobacillus rhamnosus has the effects of reducing inflammatory response of vascular endothelium and reducing oxidative stress level so as to promote repair and regeneration of vascular endothelial cells, improve vascular elasticity and quickly improve hypertension; the anti-thrombus effect can be realized. Meanwhile, by optimizing the condition parameters of the preparation process of the metabolite preparation and combining anaerobic fermentation and aerobic fermentation on the lactobacillus rhamnosus, the advantage that metabolites are comprehensive and rich is achieved, and the metabolite preparation has good practical application value.

In one aspect, the invention provides compositions and methods for preventing, reducing, and / or treating a disease, disorder or condition associated with fibrin-induced activation of the complement system and the associated activation of the coagulation and / or contact systems comprising administering a therapeutic amount of a MASP-2 inhibitory antibody to a subject in need thereof. In some embodiments, the methods of the invention provide anticoagulation and / or antithrombosis and / or antithrombogenesis without affecting hemostasis. In one embodiment of this aspect of the invention, the compositions and methods are useful for treating a subject is suffering from, or at risk of developing, a disease, disorder or condition associated with complement-related inflammation, excessive coagulation or contact system activation initiated by fibrin or activated platelets.

The invention relates to a medical device for treating aneurysms, in particular a stent, including a compressible and expandable grid structure made up of grid elements. The grid structure has at least one closed cell ring which includes at most 12, in particular at most 10, in particular at most 8, in particular at most 6 cells directly adjacent to one another in a circumferential direction of the grid structure. The grid structure is provided at least in certain portions with a covering made of an electrospun fabric which has pores of irregular sizes. The covering includes over a surface area of 100 000 μm2 at least 10 pores which have a size of at least 15 μm2. The covering has a biocompatible, in particular antithrombogenic and / or endothelialization-promoting coating.

A series of sofalcone derivatives are provided.SOLUTION: A series of sofalcone derivatives provided by the present invention are, for example, compounds having a structure of formula (I), and have platelet aggregation inhibitory and antithrombotic effects. The sofalcone derivatives of the present invention are TxA2 receptor antagonists, have an inhibitory effect on platelet agglutination, and do not easily affect the hemostatic function. The present invention also provides a method for preparing the sofalcone derivative, and a method for using the sofalcone derivative for preventing or treating thrombotic diseases, or for inhibiting platelet aggregation.SELECTED DRAWING: None

Refreshing stylets, catheter systems, and methods thereof. The refreshing stylet can be configured to fit within a lumen of a catheter such as hemodialysis catheter. The refreshing stylet can include an elongated hollow body having a proximal portion coupled to a needleless connector, a distal portion ending in a distal tip, an interior surface, an exterior surface, and a side hole. The exterior surface can be coated with a sustained-release formulation including one or more anti-thrombotic agents. The sustained-release formulation can be configured to contact a luminal surface of the catheter and prevent thrombus formation thereon. The side hole can be configured to provide a locking solution to the lumen of the catheter for locking the catheter between uses.

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

The application discloses a nitrogen acetylated carbazole alkaloid, and the structure is selected from one of the following structures: The application discloses a nitrogen acetylated carbazole alkaloid produced by fermentation of streptomyces J1074, and provides a biosynthetic preparation method, which is more green and environmental protection, and cost reduction compared with a chemical synthesis method; the compound ATC-A provided by the application shows significant antithrombotic activity in a thrombotic zebrafish model, which may be related to down-regulation of gene expression related to platelet activation and blood coagulation cascade, and has important development prospect and clinical application value.

Novel binding molecules comprising humanized antibodies, fragments, variants, and derivatives thereof, as well as compositions, methods, and kits comprising the same, are described, wherein the binding molecules specifically bind to FX1 and FX1a. The binding molecules are capable of binding to the factor X1A2 domain and forming immune complexes, thereby disrupting the contact activation molecule complex without affecting the activity or activation of hemostatic factor XI. The binding molecules disclosed herein are suitable for safely inhibiting thrombosis and inflammation without impairing hemostasis. Thus, the binding molecules, compositions, methods, and kits provided herein are intended for treating diseases and conditions, particularly those associated with thrombosis and inflammation. In addition, polynucleotides encoding the binding molecules disclosed herein, vectors comprising the polynucleotides, and host cells for producing the polynucleotides are also provided.

Provided are a novel antithrombotic antibody targeting a blood coagulation factor FIXa-FVIIIa binding site and an application thereof.SOLUTION: The present invention provides a novel antithrombotic antibody, which targets FIXa and has unique properties, specifically targets the binding site of blood coagulation factors FIXa and FVIIIa, reduces the formation of FVIIIa-FIXa complex, blocks the conversion of FX to FXa, and exerts an antithrombotic effect. The antibody of the present invention has an appropriate antithrombotic performance and a large effective therapeutic concentration window, but does not increase the bleeding risk, which can achieve the need for moderate antithrombosis and effectively avoid the bleeding problem caused by excessive action in clinical applications. The present invention also discloses methods of screening for drugs that target the FIXa-FVIIIa binding site.SELECTED DRAWING: Figure 1A

The invention relates to a preparation method of an artificial blood vessel, the artificial blood vessel is composed of a porous support layer, a biodegradation layer and an antithrombotic layer, and the method comprises the following steps: soaking an expanded polytetrafluoroethylene substrate with silver nitrate doped polyvinyl pyrrolidone-poly-N-isopropylacrylamide to obtain the porous support layer; and then assembling a biodegradable material and an antithrombotic material as a biodegradable layer and an antithrombotic layer. The invention also relates to the artificial blood vessel prepared by the method.

The present application relates to the field of biomedicine technology, and in particular to the use of an antithrombotic small molecule compound BPTU (CAS No. 870544-59-5) as a colistin adjuvant for synergistic anti-Gram-negative bacteria, wherein the antithrombotic small molecule compound BPTU comprises a compound as shown in Formula I; the use of the antithrombotic small molecule compound BPTU as a colistin adjuvant for synergistic anti-Gram-negative bacteria, BPTU and colistin have a synergistic antibacterial effect on Gram-negative bacteria, the outer membrane of Gram-negative bacteria can act as a drug barrier, and colistin has membrane-breaking activity, and colistin breaks the barrier effect of the cell membrane to assist BPTU in entering the cell to exert its antibacterial activity. Therefore, the combined use of the antithrombotic small molecule compound BPTU and colistin has broad application prospects in the treatment of Gram-negative bacteria.

Novel methods, compositions and kits for using lymphatic targeting anti-thrombosis (LTAT) molecules are provided herein. The LTAT molecules can be used to treat or prevent lymphatic thrombosis resulting particularly from infection or inflammation in the intestine.

The invention belongs to the technical field of medicines, and discloses application of pantethine in preparation of medicines for preventing and / or treating thrombotic diseases or medicines for inhibiting platelet activation or regulating vascular endothelial cell functions. In-vivo and in-vitro experiments prove that pantethine can remarkably relieve thrombus load in a mouse thrombus model, down-regulate expression of vWF (von Willebrand Factor), up-regulate expression of TFPI (Tissue Factor Path Inhibitor) and TH BD (Thromboregulatory Protein), and antagonize platelet adhesion, aggregation and activation induced by a platelet activator. The action mechanism is closely related to inhibition of reactive oxygen species (ROS) generation and NF-kappa B signal channel activation, and improvement of endothelial cell functions. It can be known from the invention that pantethine plays an antithrombotic role from multiple aspects, and is suitable for preparation of antithrombotic drugs for prevention or treatment. The invention provides a new drug choice for prevention and treatment of thrombotic diseases.

The invention discloses a traditional Chinese medicine composition for treating ischemic stroke and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from, by weight, 7-10 parts of salvia miltiorrhiza, 10-20 parts of astragalus membranaceus, 4-8 parts of ligusticum wallichii, 2-4 parts of scalded leeches, 2-4 parts of ground beetles, 2-4 parts of gastrodia elata, 4-8 parts of scorpions, 4-8 parts of polygala tenuifolia, 4-8 parts of acorus tatarinowii, 7-10 parts of red peony roots, 4-8 parts of carthamus tinctorius, 4-8 parts of angelica sinensis and 4-8 parts of peach kernels. According to the application, the compatibility structure is rigorous, the primary and secondary effects are clear, through multi-target intervention (antithrombosis, blood flow improvement and nerve protection), the advantages of'compound compatibility and overall adjustment 'of traditional Chinese medicine are embodied, and the aspects of movement, vision, language, cognitive functions and the like are remarkably improved.

The invention relates to the technical field of medical instruments, in particular to an internal and external fiber coated intravascular stent as well as a preparation method and application thereof. An inner fiber covering film and an outer fiber covering film with certain functions are respectively prepared by utilizing a coaxial electrostatic spinning technology, and the fiber covering film with a core-shell structure is prepared. The inner-layer fiber covering film takes a degradable polymer as a shell layer preparation raw material, so that the shell layer can be degraded within a certain time, thrombus and inflammation resistance is realized, and endothelialization is promoted; the anti-thrombus substance loaded on the shell layer is used for resisting acute thrombus, and can be used as a protective layer to ensure the activity of the substance for promoting vascular endothelial growth in the core layer, and the load can realize a slow release function, so that the loss of expected functions due to quick release of the load is avoided. The outer fiber membrane takes a degradable polymer as a shell layer preparation raw material, so that the shell layer can be degraded within a certain time, and tissue integration and infection resistance are promoted; antibacterial substances are loaded on the core layer and are slowly released under the wrapping of the shell layer.

The invention discloses a 5 / 8 / 5 chitosan clostridium diterpenoid compound, a biosynthetic gene cluster and application of the biosynthetic gene cluster, and relates to the technical field of biological medicines. A 5 / 8 / 5 chitin type diterpenoid biosynthetic gene cluster Thm in trichoderma harzianum is identified through a genome mining system, chitin diterpenoid compounds with diversified structures are obtained by means of heterologous expression, the obtained compounds are subjected to anti-thrombotic activity comprehensive evaluation, and the result shows that the compounds 6 and 31 can obviously inhibit vascular thrombosis, the compound 6 has a remarkable inhibition effect on collagen-induced platelet aggregation, and the compound 31 has a better inhibition capability on thrombin-induced platelet activation. The compounds 6 and 31 show powerful antithrombotic effects in artery, vein and pulmonary artery thrombosis models, so that powerful technical support is provided for development of antithrombotic drugs.

The invention discloses a natural functional component for preventing and improving cardiovascular diseases of pets. The natural functional component comprises an earthworm protein extract and a leech extract, the earthworm protein extract accounts for 20wt%-40wt% of the natural functional components; the ratio of the leech extract in the natural functional components is 10wt%-30wt%; the invention also comprises a feed containing the natural functional components for preventing and improving cardiovascular diseases of pets. The traditional Chinese medicine composition has the effects of resisting blood coagulation, thrombus, inflammation and oxidative stress, can prevent thrombosis, relieve inflammatory response, reduce free radical damage and protect the health of heart and cerebral vessels, and plays a role in preventing and improving cardiovascular diseases of pets; the pet feed additive can be added into feed to protect pet health.

The invention relates to a medical device, in particular a stent or flow diverter, comprising a mesh structure, in particular a self-expandable mesh structure, wherein the mesh structure comprises at least one mesh structure element (10) which is encased, in particular in its entirety, by a nanostructured coating formed from fibrin nanofibres (11, 12), wherein the nanostructured coating has a first layer (L1) which forms a matrix, in particular a felt-like or fleece-like matrix, of interconnected fibrin fibres (11), wherein some fibrin fibres (12) protrude freely beyond the first layer (L1) and form a second layer (L2) comprising a single-fibre structure, in particular a pile-like single-fibre structure, and wherein the nanostructured coating additionally contains a polynucleic acid-based or peptide-base KLF5 inhibitor that is integrated into the first layer (L1) and / or the second layer (L2).

The invention discloses preparation of a nano-drug with NO catalytic performance and application of the nano-drug in treatment of infectious endocarditis. The preparation method comprises the following steps: respectively dissolving molybdate and hydrophosphate in water, then stirring and mixing the two solutions, and carrying out self-assembly to form oxidized molybdenum-based Keggin type heteropolyacid, namely the nano-drug (OX) with NO catalytic performance. The nano-drug prepared by the invention has GSNO catalytic characteristics and multiple antibacterial characteristics, also has antithrombotic and vascular regulation functions, can efficiently catalyze endogenous GSNO to generate NO, and realizes efficient treatment of infectious endocarditis through the synergistic effect of double functions of oxidation antibacterial-NO regulation.

The present invention belongs to the fields of polypeptide synthesis and biomedicine technology, and specifically relates to a polypeptide PM7 and its application in preventing and treating thrombosis. The present invention obtains an original polypeptide from the transcriptome of the salivary gland of the leech Philippine cattle leech, and truncates the original polypeptide to bind to the fibrinogen binding site of thrombin, thereby interfering with the activity of thrombin. Furthermore, {d-Phe}-PRP is added to the N-terminus of the truncated polypeptide, and {d-Phe}-PRP and the truncated polypeptide are connected with a connecting polypeptide to obtain the polypeptide PM7. The polypeptide PM7 of the present invention has the activity of inhibiting thrombin, has a shorter half-life in the body, and is highly safe, thereby achieving the effect of preventing and treating thrombosis.

Provided herein is a device including a housing having a proximal end, a distal end, and a sidewall therebetween defining an interior, a fluid conduit displaceably received within the housing interior and having a proximal end and a distal end, the fluid conduit having a first conduit portion at the proximal end of the fluid conduit and a second conduit portion at the distal end of the fluid conduit, wherein the fluid conduit is configured to be advanced from a first, proximal position in which the second conduit portion does not extend beyond a distal end of a catheter of the intravenous catheter assembly to a second, distal position in which the second conduit portion extends beyond a distal end of a catheter of the intravenous catheter assembly, wherein at least a portion of the fluid conduit is configured to be antithrombogenic.

The application discloses a polypeptide FXIa inhibitor FXIapepin with high inhibition and high specificity. Since FXIa can be used as a low hemorrhage risk anti-thrombus treatment target, the polypeptide inhibitor can be used for preparing a drug for developing a low hemorrhage risk treatment or prevention of a thrombotic disease, and has a wide application prospect.

The invention provides an isoquinoline derivative with a novel structure, a pharmaceutically acceptable salt thereof, a preparation method of the isoquinoline derivative, a pharmaceutical composition containing the isoquinoline derivative and pharmaceutical application of the isoquinoline derivative, and belongs to the technical field of medicines. In-vitro experiments show that the isoquinoline derivative has significant inhibitory activity on arachidonic acid-induced platelet aggregation, and the antiplatelet activity of part of compounds is superior to that of aspirin. In a rat carotid artery thrombosis model induced by FeCl3, the isoquinoline derivative remarkably prolongs thrombosis time and reduces thrombus weight, and the in-vivo antithrombotic curative effect of the isoquinoline derivative is equivalent to that of aspirin and ticagrelor. A mouse tail bleeding model shows that the side effects of bleeding amount and bleeding time of the isoquinoline derivative are obviously lower than those of aspirin and ticagrelor. Therefore, the series of isoquinoline derivatives have the advantages of efficient antithrombotic effect and low bleeding risk, and have good application prospects in preparation of drugs for preventing and treating thrombotic diseases. In addition, the preparation method provided by the invention has the advantages of easily available raw materials, simple steps and strong operability, and the obtained target product has high quality and good efficiency.

The invention belongs to the technical field of biological materials, and particularly discloses a construction method of an anti-protein adsorption and antithrombotic graphene oxide coating, which comprises the following steps: step 1, carboxylating graphene oxide to obtain carboxylated graphene oxide nanoparticles; step 2, grafting heparin to the carboxylated graphene oxide nanoparticles; step 3, the graphene oxide-heparin nanoparticles are combined with polyethylene glycol, and graphene oxide-heparin-polyethylene glycol nanoparticles are obtained; and step 4, combining the graphene oxide-heparin-polyethylene glycol nanoparticles with a biological material. The preparation method has the advantages that the biocompatibility of the medical cardiovascular biological material is improved, the protein adsorption resistance and the thrombus resistance of the medical cardiovascular biological material are improved, and the in-vivo stability of the biological material is improved.

The invention relates to a medical device, in particular a stent or flow diverter, comprising a mesh structure, preferably a self-expanding mesh structure, wherein the mesh structure comprises at least one mesh structure element (10) which is encased, in particular in its entirety, by a nanostructured coating formed from fibrin nanofibres (11, 12), wherein the nanostructured coating has a first layer (L1) which forms a matrix, in particular a felt-like or fleece-like matrix, of interconnected fibrin fibres (11), wherein some fibrin fibres (12) protrude freely beyond the first layer (L1) and form a second layer (L2) comprising a single-fibre structure, in particular a pile-like single-fibre structure, and wherein the nanostructured coating additionally contains retinoic acid and / or a synthetic retinoid, which is integrated into the first layer (L1) and / or the second layer (L2).